Neuronoff Secures $4.5M Funding to Launch Injectrode Platform for Chronic Pain Treatment

What's Happening?

Neuronoff, Inc., a clinical-stage medical device company based in Cleveland, has successfully closed an oversubscribed $4.5 million financing round. This funding is aimed at advancing the company's Injectrode platform, a minimally invasive pain treatment device, towards FDA clearance and commercial launch. The Injectrode platform is designed to offer a drug-free alternative to traditional neuromodulation systems, eliminating the need for surgical incisions and visible scars. The device, which is delivered via an 18-gauge needle, targets interventional pain physicians, spinal surgeons, podiatrists, and other specialists treating chronic pain. Neuronoff plans to scale production to 1,000 units annually and prepare for a limited U.S. launch in 2026.

Why It's Important?

The development of the Injectrode platform represents a significant advancement in the field of neuromodulation, offering a cost-effective and less invasive treatment option for chronic pain. By reducing healthcare costs by 50% or more compared to traditional methods, Neuronoff aims to improve patient access and streamline the treatment process for clinicians. This innovation could potentially lead to broader adoption of neuromodulation therapies, benefiting patients, physicians, providers, and payers alike. The platform's design also allows for applications beyond pain management, indicating its potential impact across various therapeutic areas.

What's Next?

Neuronoff is preparing for the commercial launch of the Injectrode platform in 2026, with plans to share additional details at the North American Neuromodulation Society Annual Meeting in January 2026. The company has also established a subsidiary to commercialize the platform for an undisclosed indication affecting approximately 16 million U.S. adults. As the platform advances toward FDA clearance, Neuronoff continues to engage in positive regulatory interactions and comprehensive preclinical validation.

Beyond the Headlines

The Injectrode platform's ability to provide aesthetically pleasing outcomes without the need for opioids or surgery could lead to a paradigm shift in chronic pain treatment. By optimizing for CMS lead placement codes, the platform may reduce administrative burdens for clinicians, allowing them to focus more on patient care. This development highlights the growing trend towards minimally invasive medical technologies that prioritize patient comfort and accessibility.